EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Metastatic extramammary Paget’s disease successfully treated by trastuzumab deruxtecan: a rare case report

Lien-Ping Chou, Ming-Yang Lee, Chien-Liang Fang, Chun-Liang Tung, I-Li Lin, Cheng-Huang Shen

Frontiers in Medicine · 24.06.2026 · 13

DOI: 10.3389/fmed.2026.1831490 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Medicine, online erschienen am 24.06.2026. Verfasst von Lien-Ping Chou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metastatic extramammary Paget’s disease (mEMPD) is a rare cancer with a poor prognosis. Approximately 40% of cases overexpress the Her2/neu protein, making it a critical therapeutic target for precision-based systemic treatment. Case presentation A 73-year-old man presented with a chronic erythematous patch on the left supra-pubic and scrotal area that had been slowly enlarging over months. A tender right groin mass developed recently. Imaging revealed right inguinal lymphadenopathy with necrosis, para-aortic lymph node involvement, bladder wall lesions, and right hydronephrosis. A skin biopsy confirmed the diagnosis of extramammary Paget’s disease (EMPD), and invasive EMPD was subsequently confirmed through the excision of metastatic lymph nodes in the right groin. The immunochemical stains of the carcinoma reveal low Her2/neu expression (++/+++). Next-generation sequencing (NGS) demonstrated a high tumor mutation burden (30Muts/Mb), along with ERBBR2, PIK3CA, and PTEN mutations. Initially, he received trastuzumab and pembrolizumab. However, there was no clinical response. Then, he was treated with trastuzumab deruxtecan (anti-Her2/neu antibody–drug conjugates, ADC). A partial response was noted clinically and radiologically, including the regression of lymphadenopathy and bladder lesion. EMPD with low Her2/neu expression and high TMB may benefit more from anti-Her2/neu ADC rather than from immune checkpoint inhibitors combined with anti-Her2/neu antibodies.

Discussion

HER2-targeted strategies, including trastuzumab-docetaxel and T-DM1, show high efficacy in mEMPD. This paradigm shift toward molecularly driven, customized treatments optimizes clinical outcomes while maintaining patient performance status in this rare malignancy.

Schlagwörter

Stichwörter der Autor:innen

Next-generation sequencingPaget diseaseextramammory Paget diseasetarget therapytrastuzumab deruxtecan

Autor:innen und Institutionen

  • Department of Urology, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.
  • Department of Hematology and Oncology, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.
  • Division of Plastic and Reconstruction Surgery, Department of Surgery, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.
  • Department of Pathology, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.
  • Department of Radiology, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.

Zitieren

APA

Chou, L. P., Lee, M. Y., Fang, C. L., Tung, C. L., Lin, I. L., & Shen, C. H. (2026). Metastatic extramammary Paget’s disease successfully treated by trastuzumab deruxtecan: a rare case report. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1831490

Vancouver

Chou LP, Lee MY, Fang CL, Tung CL, Lin IL, Shen CH. Metastatic extramammary Paget’s disease successfully treated by trastuzumab deruxtecan: a rare case report. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1831490

BibTeX
@article{Chou2026,
  author = {Chou, Lien-Ping and Lee, Ming-Yang and Fang, Chien-Liang and Tung, Chun-Liang and Lin, I-Li and Shen, Cheng-Huang},
  title = {Metastatic extramammary Paget’s disease successfully treated by trastuzumab deruxtecan: a rare case report},
  journal = {Frontiers in Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fmed.2026.1831490}
}
Kostenlos starten →